Skip to main content
Premium Trial:

Request an Annual Quote

Smith Joins Orchid Cellmark as VP and CFO; Dermtech Taps Quackenbush for SAB; Transgenomic Hires Richards as Senior VP; and Others

NEW YORK (GenomeWeb News) - Orchid Cellmark has named James Smith to the post of VP and CFO. Smith formerly was executive VP and CFO of Aphton, and before that he was VP and global controller of Ansell/ Smith.He also served as a senior executive in finance and accounting at Wyeth and American Cyanamid Company.

John Quackenbush has joined Dermtech’s scientific advisory board. Quackenbush is a professor of biostatistics and computational biology at the Dana-Farber Cancer Institute and a professor of computational biology and bioinformatics at the Harvard School of Public Health.

Transgenomic has named Chad Richards as senior VP of sales and marketing. Richards formerly was national sales director of the Cancer Diagnostics Division for Quest Diagnostics, and before that he was involved in sales and marketing at Ventana Medical Systems.

Oxford Genome Sciences has added Walter Bodmer to its scientific advisory board. Bodmer is head of the Cancer and Immunogenetics laboratory in the Weatherall Institute of Molecular Medicine at the University of Oxford. Bodmer formerly was director general of the Imperial Cancer Research Fund for a dozen years, and before that he was a professor of genetics at Oxford.

Nextbio has named Michael Silber to its scientific advisory board. Silber formerly was senior VP and site head of preclinical R&D at Roche Pharmaceuticals. He also was president of R&D at Johnson & Johnson/Alza, director of genomic and proteomic sciences at Pfizer Research, senior director and division head of pharmacology and toxicology at Cetus, and director and head of drug metabolism at Lederle.

Third Wave Technologies has appointed David Arnold to its board of directors. Arnold is a former VP and CTO of Kennametal, where he worked for 24 years.

Epigenomics has named the first members for its new colorectal cancer medical advisory board. Appointees include Douglas Rex, professor of medicine at Indiana University’s School of Medicine; Philip Schoenfeld, associate professor in the department of internal medicine at the University of Michigan’s School of Medicine; Deborah Fisher, assistant professor of medicine at Duke University; and Scott Ramsey, associate professor of medicine and health services at the Fred Hutchinson Cancer Research Center.

Fluorotechnics has appointed Günter Thebeling to head its sales and marketing team. Thebeling formerly was strategic marketing director for proteomics products at GE Healthcare and was responsible for managing relationships with pharmaceutical partners and with scientific organizations such as the Human Proteome Organization.

Fran Tuttle has been appointed to join Xceed Molecular’s board of trustees. Tuttle is president and CEO of HX Diagnostics, and formerly was CEO of Protedyne, senior VP of near patient testing at Bayer Diagnostics. Before that she worked at Chiron Diagnostics.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.